Cytoreductive Nephrectomy Plus Active Surveillance Continues to Show Promise in mRCCNovember 12th 2021
A select group of patients with metastatic renal cell carcinoma may benefit from cytoreductive nephrectomy followed by active surveillance as an alternative option to systemic therapy.
Proactive Approach for Managing Adverse Reactions Associated With Lenvatinib/Pembrolizumab Needed in Advanced RCCNovember 5th 2021
As lenvatinib plus pembrolizumab combination therapy results in a wide range of adverse effects, some which even led to discontinuation of the treatment, investigators suggest a proactive strategy for patients with advanced renal cell carcinoma.
Cell Cycle Proliferation and Epithelial-Mesenchymal Transition Pathway Scores Predictive of Recurrence and Survival for ccRCCNovember 5th 2021
Research from the 2021 International Kidney Cancer Symposium North America identified prognostic value in cell cycle proliferation and epithelial-mesenchymal transition pathway scores in clear cell renal cell carcinoma in predicting survival and recurrence.
Genes Influence Outcomes of Treatment Sequences in Clear Cell RCCNovember 6th 2016
Specific tumor genotypes could represent distinct subtypes of clear cell renal cell carcinoma, according to a new analysis of the RECORD-3 trial. Genotyping could potentially help guide treatment decisions if the results can be validated.
Nivolumab Can Still Benefit RCC Patients Who Stop Due to Immune-Related ToxicityNovember 6th 2016
A small study found that patients with metastatic renal cell carcinoma (mRCC) who discontinue nivolumab due to immune-related adverse events can continue to derive benefit even after cessation of therapy.
Cabozantinib Tops Everolimus in Advanced RCC, Regardless of MET ExpressionNovember 5th 2016
Expression of MET as measured by immunohistochemistry was not associated with any difference in the performance of cabozantinib as compared with everolimus in patients with advanced renal cell carcinoma.
Surveillance of Small Renal Masses Yields Good Outcomes, Has ChallengesNovember 4th 2016
Active surveillance of small renal masses has been shown in recent years to be a generally safe and reasonable approach, though there are a number of factors for clinicians to keep in mind in taking this path.